RxDoctor Payments Data

Cindy Greenberg, MD

Dermatopathology · Kingwood, TXNPI 1649247115

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.9% of the total across 337 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,387 and has fallen 96.5% since, to $48 in 2025.

$6,620in general payments, 2019–2025

Across 337 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$856
  • Sanofi$543
  • Amgen$505
  • Regeneron Healthcare Solutions, Inc.$487
  • Novartis$380
  • plus $3K from 22 others

What the payments were for

  • Food & beverage$6,615100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,620 in reported general payments places this provider in the 70th percentile of 54 dermatopathology providers in Texas.

See all dermatopathology providers in Texas

Medicare billing

Part B allowed, 2024
$199,289
Medicare patients
816
Services billed
4,075

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast11$57,046
Fluorouracil32$2,149
Calcipotriene12$1,695
Doxycycline Hyclate87$1,603
Clobetasol Propionate32$1,267
Metronidazole16$1,150
Triamcinolone Acetonide46$498
ValacyclovirValacyclovir Hcl12$368
Ketoconazole27$360
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet12$227
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav13$133
Hydrocortisone32$127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$505$57,04611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 54 dermatopathology providers in Texas.

Other dermatopathology in Kingwood

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →